GlassScriptPhysician profile
David J Burrier
NPI 1699769422
$2,028.03
in general payments reported to CMS, 2019-2025
22 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $200 · 2021: $257 · 2022: $49.06 · 2023: $23.66 · 2024: $152 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $652.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $419.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Corcept Therapeutics | $102.01 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $87.83 | 2019-2024 | Trelegy Ellipta |
| Allergan, INC. | $72.81 | 2019-2020 | |
| Abbvie INC. | $64.15 | 2025 | |
| Avanir Pharmaceuticals, INC. | $58.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.23 | 2019-2020 | |
| Lilly USA, LLC | $57.00 | 2019-2025 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $52.59 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.02 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.13 | 2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $40.01 | 2019 | |
| Phathom Pharmaceuticals, INC. | $36.36 | 2024 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $36.29 | 2025 | Auvelity |
| Mylan Specialty L.P. | $30.12 | 2019 | |
| Pfizer INC. | $27.42 | 2019-2020 | |
| Corium, LLC | $26.65 | 2024 | Azstarys |
| Abbott Laboratories | $25.77 | 2019 | |
| Merck Sharp & Dohme LLC | $22.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Burrier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.